About bortezomib
Proteasome inhibitor anticancer medicine
Used for
- Multiple myeloma
- Mantle cell lymphoma
Usual adult dose
Usually 1.3 mg/m² by injection twice weekly for two weeks, followed by a rest week; schedules vary by cancer regimen.
Common side effects
- Peripheral nerve damage, numbness, or tingling
- Low blood counts
- Nausea, diarrhea, or constipation
- Fatigue, fever, or shingles
Important warnings
- Can cause serious nerve, blood, liver, or lung problems.
- Shingles may reactivate; preventive antiviral treatment is often considered.
- May cause low blood pressure and raise blood sugar.
- Given by healthcare professionals; injection route and schedule depend on treatment.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for seven months afterward for women; four months for men with partners who could become pregnant.
Breastfeeding
Breastfeeding is not recommended during treatment and for two months after the last dose.
Interactions
- Strong CYP3A4 inhibitors may increase bortezomib exposure.
- Strong CYP3A4 inducers may reduce its effectiveness.
- Medicines that lower blood pressure may increase dizziness or fainting.
- Medicines causing nerve damage may worsen neuropathy.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.